Skip to main content
SpringerLink
Log in

Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Purpose

Recurrence of glioblastoma (GB) occurs in most patients after standard concomitant temozolomide-based radiochemotherapy (CTRC). Bevacizumab (BV), an anti-VEGF antibody, has an effect on progression-free survival (PFS) but not on overall survival (OS). However, a small part of the patients experience a survival, longer than expected. This retrospective study aims to characterize long responder (LR) patients treated with BV for a first or second GBM recurrence.

Methods

Medical records from patients (814) who received BV for a first or second recurrence of primary glioblastoma between September 2010 and September 2015, and initially treated by CTRC were analyzed. Patients, who had at least a stable disease according to RANO criteria at 12 months from the start of BV, were included. Patients who had, a secondary GB, or received BV in neoadjuvant or adjuvant setting were excluded.

Results

We focused on 65 LR patients without progression 12 months after the first injection of BV (8%). Median PFS was 21.7 months [95% CI (19.3; 27.2)] and median OS was 31.1 months [95% CI (24.3; 37.5)] from the start of BV. No prognostic factor was associated with OS in multivariate analysis. Karnofsky performance status, neurological status and corticosteroid dose were stable at 12 months.

Conclusions

Our results highlight that among patients receiving bevacizumab in first or second recurrence, one patient out of twelve could be classified as LR. A median OS of 31.1 months from the start of BV could be expected in this subpopulation. These findings reinforce the potential benefit of the use of BV in the situation of recurrence.

256 words

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

    CAS  Google Scholar 

  2. Jain RK, di Tomaso E, Duda DG et al (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610–622

    CAS  PubMed  Google Scholar 

  3. Jain RK (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26(5):605–622

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722

    CAS  PubMed  Google Scholar 

  6. Wong ET, Gautam S, Malchow C et al (2011) Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Cancer Netw JNCCN 9(4):403–407

    CAS  Google Scholar 

  7. Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377(20):1954–1963

    CAS  PubMed  Google Scholar 

  8. Lombardi G, Pambuku A, Bellu L et al (2017) Effectiveness of antiangiogenic drugs in glioblastoma patients: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 111:94–102

    PubMed  Google Scholar 

  9. Schaub C, Tichy J, Schäfer N et al (2016) Prognostic factors in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol 129(1):93–100

    CAS  PubMed  Google Scholar 

  10. Bi WL, Beroukhim R (2014) Beating the odds: extreme long-term survival with glioblastoma. Neuro-Oncol 16(9):1159–1160

    PubMed  PubMed Central  Google Scholar 

  11. Gately L, McLachlan S-A, Philip J et al (2018) Long-term survivors of glioblastoma: a closer look. J Neurooncol 136(1):155–162

    PubMed  Google Scholar 

  12. Johnson DR, Omuro AMP, Ravelo A et al (2018) Overall survival in patients with glioblastoma before and after bevacizumab approval. Curr Med Res Opin 34(5):813–820

    CAS  PubMed  Google Scholar 

  13. Chen C, Ravelo A, Yu E et al (2015) Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices. J Neurooncol 122(3):595–605

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Gramatzki D, Roth P, Rushing EJ et al (2018) Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Ann Oncol Off J Eur Soc Med Oncol. https://doi.org/10.1093/annonc/mdy106

    Article  Google Scholar 

  15. Bronnimann C, Izquierdo C, Cartalat S et al (2018) Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy. J Neurooncol. https://doi.org/10.1007/s11060-018-2780-1

    Article  PubMed  Google Scholar 

  16. Balaña C, Estival A, Pineda E et al (2017) Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab. Neuro-Oncol Pract 4(1):15–23

    Google Scholar 

  17. Hertenstein A, Hielscher T, Menn O et al (2016) Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. J Neurooncol 129(3):533–539

    CAS  PubMed  Google Scholar 

  18. Anderson MD, Hamza MA, Hess KR, Puduvalli VK (2014) Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro-Oncol 16(6):823–828

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Reardon DA, Herndon JE, Peters KB et al (2012) Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer 107(9):1481–1487

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Hamza MA, Mandel JJ, Conrad CA et al (2014) Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol 119(1):135–140

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Piccioni DE, Selfridge J, Mody RR et al (2014) Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro-Oncol 16(6):815–822

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Wiestler B, Radbruch A, Osswald M et al (2014) Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. J Neurooncol 117(1):85–92

    CAS  PubMed  Google Scholar 

  23. Franceschi E, Lamberti G, Paccapelo A et al (2018) Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab? J Neurooncol 20:18. https://doi.org/10.1007/s11060-018-2873-x

    Article  CAS  Google Scholar 

  24. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J Clin Oncol 28(11):1963–1972

    PubMed  Google Scholar 

  25. Ellingson BM, Chung C, Pope WB et al (2017) Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol 134(3):495–504

    CAS  PubMed  Google Scholar 

  26. Levin VA, Bidaut L, Hou P et al (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487–1495

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Duerinck J, Clement PM, Bouttens F et al (2015) Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. J Neurol 262(3):742–751

    CAS  PubMed  Google Scholar 

  28. Wong ET, Lok E, Gautam S, Swanson KD (2015) Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer 113(11):1642

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Flieger M, Ganswindt U, Schwarz SB et al (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol 117(2):337–345

    CAS  PubMed  Google Scholar 

  30. Palmer JD, Bhamidipati D, Song A et al (2018) Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter? J Neurooncol 140(3):623–628

    CAS  PubMed  Google Scholar 

  31. Brandes AA, Bartolotti M, Tosoni A et al (2015) Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist 20(2):166–175

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Vredenburgh JJ, Cloughesy T, Samant M et al (2010) Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 15(12):1329–1334

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Taphoorn MJB, Henriksson R, Bottomley A et al (2015) Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 33(19):2166–2175

    CAS  PubMed  Google Scholar 

  34. Dirven L, van den Bent MJ, Bottomley A et al (2015) The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer Oxf Engl 1990 51(10):1321–1330

    CAS  Google Scholar 

  35. Chen C, Huang R, MacLean A et al (2013) Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol 115(2):267–276

    CAS  PubMed  Google Scholar 

  36. Lv S, Teugels E, Sadones J et al (2011) Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. Anticancer Res 31(12):4457–4463

    CAS  PubMed  Google Scholar 

  37. Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y et al (2016) Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trial. Cancer Res 76(3):525–534

    CAS  PubMed  Google Scholar 

  38. Gerber NK, Goenka A, Turcan S et al (2014) Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncol 16(9):1186–1195

    PubMed  PubMed Central  Google Scholar 

  39. Amelot A, De Cremoux P, Quillien V et al (2015) IDH-Mutation is a weak predictor of long-term survival in glioblastoma patients. PLoS ONE 10(7):e0130596

    PubMed  PubMed Central  Google Scholar 

  40. Hartmann C, Hentschel B, Simon M et al (2013) Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 19(18):5146–5157

    CAS  PubMed  Google Scholar 

  41. Levin VA, Mendelssohn ND, Chan J et al (2015) Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. J Neurooncol 122(1):145–150

    CAS  PubMed  Google Scholar 

  42. Lorgis V, Maura G, Coppa G et al (2012) Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J Neurooncol 107(2):351–358

    CAS  PubMed  Google Scholar 

  43. Ajlan A, Thomas P, Albakr A et al (2017) Optimizing bevacizumab dosing in glioblastoma: less is more. J Neurooncol 135(1):99–105

    CAS  PubMed  Google Scholar 

  44. Batchelor TT, Gerstner ER, Emblem KE et al (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110(47):19059–19064

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’Oncologie Médicale, CHU Amiens, 80054, Amiens Cedex 1, France

    M. C. Morisse, M. Boone & B. Chauffert

  2. Service de Pharmacie, CLCC Paul Strauss, Strasbourg, France

    N. Etienne-Selloum

  3. UMR 7021 CNRS, Laboratoire de Bioimagerie Et Pathologies, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France

    N. Etienne-Selloum

  4. Département de Recherche Clinique, Institut Curie Site Saint Cloud, Saint Cloud, France

    D. Bello-Roufai

  5. Service de Neuro-Oncologie, CHU Nancy, Nancy, France

    M. Blonski & L. Taillandier

  6. Service d’Oncologie Médicale, CLCC Georges-François Leclerc, Dijon, France

    V. Lorgis

  7. Service de Radiothérapie, CLCC Paul Strauss, Strasbourg, France

    G. Noël

  8. Service de Neurologie, Hôpitaux Civils de Colmar, Colmar, France

    G. Ahle

  9. Sorbonne Université, APHP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France

    A. Durán-Peña

Authors
  1. M. C. Morisse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Etienne-Selloum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Bello-Roufai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Blonski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Taillandier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Lorgis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Noël
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Ahle
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Durán-Peña
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Boone
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B. Chauffert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Chauffert.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morisse, M.C., Etienne-Selloum, N., Bello-Roufai, D. et al. Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study. J Neurooncol 144, 419–426 (2019). https://doi.org/10.1007/s11060-019-03245-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-019-03245-5

Keywords

Search

Navigation